Bovilis Blue-8

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
20-12-2021
产品特点 产品特点 (SPC)
20-12-2021
公众评估报告 公众评估报告 (PAR)
08-12-2017

有效成分:

bluetongue virus vaccine, serotype 8 (inactivated)

可用日期:

Intervet International B.V.

ATC代码:

QI04AA02

INN(国际名称):

bluetongue virus vaccine (inactivated) serotype 8

治疗组:

Cattle; Sheep

治疗领域:

Immunologicals for ovidae

疗效迹象:

SheepFor the active immunisation of sheep from 2.5 months of age to prevent viraemia* and to reduce clinical signs caused by bluetongue virus serotype 8.CattleFor the active immunisation of cattle from 2.5 months of age to prevent viraemia* caused by bluetongue virus serotype 8.*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating no presence of viral genome)

產品總結:

Revision: 4

授权状态:

Authorised

授权日期:

2017-11-21

资料单张

                                16
B. PACKAGE LEAFLET
page 16 of 20
17
PACKAGE LEAFLET:
BOVILIS BLUE-8 SUSPENSION FOR INJECTION FOR CATTLE AND SHEEP
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Intervet International BV
Wim de Körverstraat 35,
5831 AN Boxmeer
The NETHERLANDS
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Bovilis Blue-8 suspension for injection for cattle and sheep
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Each ml of vaccine contains:
Bluetongue virus inactivated, serotype 8
10
6.5
CCID
50
*
Aluminium hydroxide
6 mg
Purified saponin (Quil A)
0.05 mg
Thiomersal
0.1 mg
(* equivalent to titre prior to inactivation)
4.
INDICATION(S)
Sheep
For the active immunisation of sheep from 2.5 months of age to prevent
viraemia* and to reduce
clinical signs caused by bluetongue virus serotype 8.
*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating
no presence of viral genome)
Onset of immunity:
20 days after the second dose.
Duration of immunity:
1 year after the second dose.
Cattle
For the active immunisation of cattle from 2.5 months of age to
prevent viraemia* caused by
bluetongue virus serotype 8.
*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating
no presence of viral genome)
Onset of immunity:
31 days after the second dose.
Duration of immunity:
1 year after the second dose.
5.
CONTRAINDICATIONS
None.
6.
ADVERSE REACTIONS
An average increase in body temperature varying between 0.5 and 1.0
ºC is a common reaction
observed in sheep and cattle. It lasted not longer than 24 to 48
hours. Transient fever was observed in
rare cases. Temporary local reactions can occur very rarely at the
injection site in the form of a nodule
page 17 of 20
18
of 0.5 to 1 cm in sheep and of 0.5 to 3 cm in cattle which disappears
within 14 days, at the latest and
which may be painful. Loss of appetite can occur in very rare cases.
Hypersensitivity reactions are
very rarely observed.
The frequency of adverse re
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
page 1 of 20
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Bovilis Blue-8 suspension for injection for cattle and sheep
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of vaccine contains:
ACTIVE SUBSTANCE:
Bluetongue virus inactivated, serotype 8: 10
6.5
CCID
50
*
(* equivalent to titre prior to inactivation)
ADJUVANTS:
Aluminium hydroxide
6 mg
Purified saponin (Quil A) 0.05 mg
EXCIPIENT:
Thiomersal
0.1 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
White or pinkish-white.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Sheep and cattle.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Sheep
For the active immunisation of sheep from 2.5 months of age to prevent
viraemia* and to reduce
clinical signs caused by bluetongue virus serotype 8.
*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating
no presence of viral genome)
Onset of immunity:
20 days after the second dose.
Duration of immunity:
1 year after the second dose.
Cattle
For the active immunisation of cattle from 2.5 months of age to
prevent viraemia* caused by
bluetongue virus serotype 8.
*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating
no presence of viral genome)
Onset of immunity:
31 days after the second dose.
Duration of immunity:
1 year after the second dose.
4.3
CONTRAINDICATIONS
None.
page 2 of 20
3
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
Occasionally, the presence of maternally derived antibodies in ovines
of minimum recommended age
might interfere with the protection induced by the vaccine.
No information is available on the use of the vaccine in seropositive
bovines, including those with
maternally derived antibodies.
If used in other domestic and wild ruminant species that are
considered at risk of infection, its use in
these species should be undertaken with care and it is advisable to
test the vaccine on a small number
of animals prior to mass vaccination. The level of
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 20-12-2021
产品特点 产品特点 保加利亚文 20-12-2021
公众评估报告 公众评估报告 保加利亚文 08-12-2017
资料单张 资料单张 西班牙文 20-12-2021
产品特点 产品特点 西班牙文 20-12-2021
公众评估报告 公众评估报告 西班牙文 08-12-2017
资料单张 资料单张 捷克文 20-12-2021
产品特点 产品特点 捷克文 20-12-2021
公众评估报告 公众评估报告 捷克文 08-12-2017
资料单张 资料单张 丹麦文 20-12-2021
产品特点 产品特点 丹麦文 20-12-2021
公众评估报告 公众评估报告 丹麦文 08-12-2017
资料单张 资料单张 德文 20-12-2021
产品特点 产品特点 德文 20-12-2021
公众评估报告 公众评估报告 德文 08-12-2017
资料单张 资料单张 爱沙尼亚文 20-12-2021
产品特点 产品特点 爱沙尼亚文 20-12-2021
公众评估报告 公众评估报告 爱沙尼亚文 08-12-2017
资料单张 资料单张 希腊文 20-12-2021
产品特点 产品特点 希腊文 20-12-2021
公众评估报告 公众评估报告 希腊文 08-12-2017
资料单张 资料单张 法文 20-12-2021
产品特点 产品特点 法文 20-12-2021
公众评估报告 公众评估报告 法文 08-12-2017
资料单张 资料单张 意大利文 20-12-2021
产品特点 产品特点 意大利文 20-12-2021
公众评估报告 公众评估报告 意大利文 08-12-2017
资料单张 资料单张 拉脱维亚文 20-12-2021
产品特点 产品特点 拉脱维亚文 20-12-2021
公众评估报告 公众评估报告 拉脱维亚文 08-12-2017
资料单张 资料单张 立陶宛文 20-12-2021
产品特点 产品特点 立陶宛文 20-12-2021
公众评估报告 公众评估报告 立陶宛文 08-12-2017
资料单张 资料单张 匈牙利文 20-12-2021
产品特点 产品特点 匈牙利文 20-12-2021
公众评估报告 公众评估报告 匈牙利文 08-12-2017
资料单张 资料单张 马耳他文 20-12-2021
产品特点 产品特点 马耳他文 20-12-2021
公众评估报告 公众评估报告 马耳他文 08-12-2017
资料单张 资料单张 荷兰文 20-12-2021
产品特点 产品特点 荷兰文 20-12-2021
公众评估报告 公众评估报告 荷兰文 08-12-2017
资料单张 资料单张 波兰文 20-12-2021
产品特点 产品特点 波兰文 20-12-2021
公众评估报告 公众评估报告 波兰文 08-12-2017
资料单张 资料单张 葡萄牙文 20-12-2021
产品特点 产品特点 葡萄牙文 20-12-2021
公众评估报告 公众评估报告 葡萄牙文 08-12-2017
资料单张 资料单张 罗马尼亚文 20-12-2021
产品特点 产品特点 罗马尼亚文 20-12-2021
公众评估报告 公众评估报告 罗马尼亚文 08-12-2017
资料单张 资料单张 斯洛伐克文 20-12-2021
产品特点 产品特点 斯洛伐克文 20-12-2021
公众评估报告 公众评估报告 斯洛伐克文 08-12-2017
资料单张 资料单张 斯洛文尼亚文 20-12-2021
产品特点 产品特点 斯洛文尼亚文 20-12-2021
公众评估报告 公众评估报告 斯洛文尼亚文 08-12-2017
资料单张 资料单张 芬兰文 20-12-2021
产品特点 产品特点 芬兰文 20-12-2021
公众评估报告 公众评估报告 芬兰文 08-12-2017
资料单张 资料单张 瑞典文 20-12-2021
产品特点 产品特点 瑞典文 20-12-2021
公众评估报告 公众评估报告 瑞典文 08-12-2017
资料单张 资料单张 挪威文 20-12-2021
产品特点 产品特点 挪威文 20-12-2021
资料单张 资料单张 冰岛文 20-12-2021
产品特点 产品特点 冰岛文 20-12-2021
资料单张 资料单张 克罗地亚文 20-12-2021
产品特点 产品特点 克罗地亚文 20-12-2021
公众评估报告 公众评估报告 克罗地亚文 08-12-2017